Heart failure with preserved ejection fraction: A mini review
- 22 July 2022
- journal article
- Published by Heighten Science Publications Corporation
- Vol. 6 (1), 005-006
- https://doi.org/10.29328/journal.avm.1001016
Abstract
Over the past 20 years, there has been a surge of clinical investigations and useful trials on heart failure (HF) with preserved ejection fraction (HFpEF). HFpEF represents the largest phenotype of HF, a public health concern for its link with high mortality and rates of morbidity.Keywords
This publication has 9 references indexed in Scilit:
- Heart failure with preserved ejection fraction update: A review of clinical trials and new therapeutic considerationsCardiology Journal, 2022
- 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice GuidelinesJournal of the American College of Cardiology, 2022
- Left Atrial Circulatory Assistance in Simulated Diastolic Heart Failure Model: First in Vitro and in VivoJournal of Cardiac Failure, 2022
- Heart failure with preserved ejection fraction: An alternative paradigm to explain the clinical implications of atrial fibrillationHeart Rhythm O2, 2021
- Empagliflozin in Heart Failure with a Preserved Ejection FractionThe New England Journal of Medicine, 2021
- Similarities and Differences Between HFmrEF and HFpEFFrontiers in Cardiovascular Medicine, 2021
- Heart Failure With Preserved Ejection Fraction In PerspectiveCirculation Research, 2019
- Sympathetic and baroreflex alterations in congestive heart failure with preserved, midrange and reduced ejection fractionJournal of Hypertension, 2019
- Phenotype-Specific Treatment of Heart Failure With Preserved Ejection FractionJournal of the American College of Cardiology, 2016